Approximately 626,000 Americans will die of cancer in 2026. Nearly 53,000 will die from pancreatic cancer — soon to be the second-leading cause of cancer death in the United States. About half of patients are diagnosed with metastatic pancreatic ductal adenocarcinoma (mPDAC), the most aggressive and deadly form of the disease. It is notorious for its resistance to traditional treatment. And despite decades of research, only 3% of these patients survive five years. Globally, it represents a $73B market. At Pierogi Therapeutics, we’re using physics-based machine learning methods to develop a fundamentally new kind of cancer treatment: radiotherapeutics.
News
No announcements yet — check back soon.